(Bloomberg) — A Gilead Sciences Inc. analyst advised investors to take their profits on the company’s $26.5 billion surge amid uncertainty on how the drugmaker could generate revenue from its Covid-19 drug candidate, remdesivir.The biopharmaceutical company’s plan to make the drug “affordable” and give away free doses for the time being clouds expectations of how it can use the medicine to turn a profit, SunTrust analyst Robyn Karnauskas warned clients in a note, downgrading the stock to sell from hold.“While we commend Gilead and do believe during this pandemic the company is doing the right thing, fundamentally we find the …read more
Source:: Yahoo Finance
